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Abstract: Endothelium plays a crucial role in the maintenance of vascular tone and structure. Endothelial dysfunction is 
known to precede overt coronary artery disease. A number of cardiovascular risk factors, as well as metabolic diseases 
and systemic or local inflammation cause endothelial dysfunction. Nitric oxide (NO) is one of the major endothelium 
derived vaso-active substances whose role is of prime importance in maintaining endothelial homeostasis. Low levels of 
NO are associated with impaired endothelial function. Asymmetric dimethylarginine (ADMA), an analogue of L-arginine, 
is a naturally occurring product of metabolism found in human circulation. Elevated levels of ADMA inhibit NO 
synthesis and therefore impair endothelial function and thus promote atherosclerosis. ADMA levels are increased in 
people with hypercholesterolemia, atherosclerosis, hypertension, chronic heart failure, diabetes mellitus and chronic renal 
failure. A number of studies have reported ADMA as a novel risk marker of cardiovascular disease. Increased levels of 
ADMA have been shown to be the strongest risk predictor, beyond traditional risk factors, of cardiovascular events and 
all-cause and cardiovascular mortality in people with coronary artery disease. Interventions such as treatment with L-
arginine have been shown to improve endothelium-mediated vasodilatation in people with high ADMA levels. However 
the clinical utility of modifying circulating ADMA levels remains uncertain.  
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INTRODUCTION 
  Atherosclerotic disease is a major cause of mortality 
around the world. Conventional cardiovascular risk factors 
like hypercholesterolemia, diabetes, smoking and hyper-
tension can account for 80% of increased risk of coronary 
artery disease [1, 2]. 
  The endothelium plays a crucial role in the maintenance 
of vascular tone [3]. Endothelium-derived mediators play a 
crucial role in vascular homeostasis. Endothelium-derived 
nitric oxide (NO) is a potent endogenous vasodilator. NO is 
formed in the endothelium by the endothelial isoform of 
nitric oxide synthase (NOS) [4]. It is released in response to 
shear stress and plays an important role in flow-mediated 
dilatation [5]. Besides inducing vasodilatation, NO inhibits 
aggregation of platelets [6], inhibits adhesion of monocytes 
and leukocytes to the endothelium [7], inhibits smooth 
muscle cell proliferation [8] and inhibits oxidation of LDL 
[9]. Endothelium-derived NO also inhibits vascular inflam-
mation by suppressing the expression and activity of 
adhesion molecules and chemokines [10].  
  Together, these functions make NO a significant endo-
genous anti-atherosclerotic molecule. A reduction in NO can 
result in endothelial dysfunction and in an increased risk for 
cardiovascular disease. Endothelial dysfunction precedes 
overt atherosclerotic disease. Previous studies have shown 
endothelial dysfunction to predict the presence of cardio-
vascular disease and future cardiovascular events [11, 12]. 
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  In 1992, Vallance and co-workers reported that asym-
metric dimethylarginine (ADMA) is a naturally occurring 
endogenous inhibitor of nitric oxide (NO) synthase [13]. 
ADMA reduces NO production and consequently could thus 
lead to endothelial dysfunction and cardiovascular events. 
An increased understanding of the pathophysiology of 
atherosclerosis, particularly of the central role of endothelial 
dysfunction, has led to the emergence of plasma ADMA as a 
putative cardiovascular risk marker.  
  Studies have shown that the increased concentrations of 
ADMA found in some pathophysiological conditions are 
associated with other factors giving increased risk of 
atherosclerosis such as increasing age, hypercholesterolemia, 
hypertension, hypertriglyceridemia, diabetes mellitus, insulin 
insensitivity, hyperhomocysteinemia and renal failure [14-
21]. Furthermore, elevated plasma ADMA concentration has 
been identified as an independent risk factor for progression 
of atherosclerosis, cardiovascular death and all-cause 
mortality [22-24]. 
ADMA BIOSYNTHESIS, METABOLISM AND 
EXCRETION 
Biosynthesis 
  Dimethylarginines are the result of the degradation of 
methylated proteins [25]. The methyl groups are derived 
from S-adenosylmethionine, with involvement of the 
enzymes protein arginine methyltransferase type 1 and 2 
(PRMT1, PRMT2). PRMT-1 catalyses the formation of NG-
monomethyl-L-arginine (LNMMA) and NG,NG-dimethyl-
L-arginine (ADMA), while PRMT-2 methylates proteins to 
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arginine; SDMA) and L-NMMA [26, 27]. The asymmetri-
cally methylated arginine residues (L-NMMA and ADMA), 
but not symmetrically methylated arginine (SDMA), are 
compe-titive inhibitors of the nitric oxide synthases. The 
release of ADMA from endothelial cells is increased in the 
presence of native or oxidized LDL, possibly mediated by 
up-regulation of S-adenosylmethionine dependent methyl 
transferases [28] (Fig. 1). Moreover, recent data have shown 
that the lung appears to contain large amounts of protein-
bound ADMA, due to the high expression levels of various 
PRMTs in lung tissue [29].  
Metabolism and Excretion 
  Renal excretion plays a role in the elimination of endo-
genous ADMA and SDMA. Urinary excretion of SDMA in 
rabbits has been shown to be 30 times greater than that of 
either L-NMMA or ADMA [25]. A number of studies have 
reported increased levels of ADMA and SDMA in people 
with renal failure [21, 30]. Interestingly, haemodialysis leads 
to a lower clearance of ADMA than predicted, suggesting 
there are alternative non-renal route(s) of removal of circu-
lating ADMA [31]. 
  The specific pathway involved in metabolism of ADMA 
but not SDMA occurs via hydrolytic degradation to citrulline 
and dimethylamine catalysed by the enzyme called NG 
dimethylarginine dimethylaminohydrolase (DDAH) [32] 
(Fig. 1). 
  DDAH activity has been found in kidney, pancreas, liver, 
brain and aorta with immunoexpression also in neutrophils 
and macrophages [33, 34]. Inhibition of DDAH causes 
gradual vasoconstriction which is reversed by L-arginine 
[35]. There are two isoforms of DDAH, DDAH-1 and 
DDAH-2. DDAH-1 is usually found in tissues expressing 
neuronal NOS while DDAH-2 is predominantly found in 
tissues containing the endothelial isoform of NOS [36]. 
Increased plasma levels of glucose, oxidized LDL and 
homocysteine are associated with decreased levels of 
DDAH. Furthermore, some conventional cardiovascular risk 
factors may reduce DDAH activity by increasing oxidative 
stress [37-40]. Pharmacological inhibition of DDAH increa-
ses ADMA concentrations and reduces NO production [41]. 
  Conversely, transgenic DDAH overexpression reduces 
ADMA levels and increases NO levels [42]. In animal 
studies DDAH overexpression has been shown to promote 
















Fig. (1). Overview of pathways of synthesis and metabolism of ADMA. Methylation of arginine residues within peptides occurs through N-
methyltransferases, protein arginine N-methyltransferase-1 (PRMT-1). S-adenosylmethionine (SAM) is the methyl donor, changing to S-
adenosylhomocysteine (SAH). Proteolytic breakdown of the proteins leads to the generation of ADMA and N-monomethyl-L-arginine (L-
NMMA) within cells, and is detectable in the circulation. ADMA is an inhibitor of endothelial nitric oxide synthase (eNOS) by competing 
with its substrate L-arginine thus impairing nitric oxide (NO) production, thus leading to endothelial dysfunction and subsequently 
atherosclerosis. ADMA is eliminated partly via urinary excretion but mainly via metabolism by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH) to citrulline and dimethylamine. 84    Current Cardiology Reviews, 2010, Vol. 6, No. 2  Sibal et al. 
myocardial reperfusion injury [44] and to inhibit ADMA-
induced endothelial dysfunction in the cerebral circulation 
[45]. Interestingly, over-expression of DDAH-1 and DDAH-
2 appears to result in very similar phenotypic changes, 
whereas selective silencing of individual DDAH isoforms 
results in greatly different biological effects [46]. Thus, 
silencing of DDAH-1 resulted in increased circulating 
ADMA levels but no change in endothelium-mediated vaso-
dilation, whereas silencing of DDAH-2 resulted in signifi-
cantly reduced endothelium-mediated vasodilatation with no 
concomitant change in plasma ADMA concentration. This 
finding corresponds to the observation that DDAH-2 is the 
most abundant isoform in endothelium, whereas DDAH-1 is 
found at high expression levels in kidneys and liver. 
ADMA and its Role in Endothelial Dysfunction and 
Cardiovascular Disease 
  As noted above, ADMA is an endogenous competitive 
inhibitor of NO synthase, and thus may cause endothelial 
dysfunction [20, 47]. The link between plasma ADMA levels 
and established and emerging risk factors for progression of 
vascular disease has therefore been investigated. Putatively, 
a number of such risk factors, including obesity [48], 
hypertension [49], hypercholesterolemia [14], smoking [50], 
diabetes mellitus [51], hyperhomocysteinemia [52] and 
vascular inflammation [53] might mediate their deleterious 
effects on the vascular wall through the dysfunction of the 
endothelial L-arginine/NO pathway. In each of these 
conditions, ADMA plasma levels have been shown in case-
control studies to be elevated compared to healthy controls. 
  Local intra-arterial infusion of ADMA can significantly 
reduce forearm blood flow [47]. Moreover, intravenous 
infusion of ADMA increased mean blood pressure by 6% 
and systemic vascular resistance by 24%, while reducing the 
effect of exercise on cardiac output (by ~15%), heart rate, 
and vascular responsiveness [54]. 
ADMA and Endothelial Function: Clinical Studies 
  In a randomized, double-blind, placebo-controlled study 
investigating endothelial function as measured by brachial 
artery flow-mediated dilatation (FMD), serum ADMA and 
serum L-arginine levels in 49 hypercholesterolemic indivi-
duals were compared to individuals with normal cholesterol 
levels. People with hypercholesterolemia had impaired 
endothelial function, increased ADMA levels and decreased 
L-arginine/ADMA ratio. ADMA levels were inversely 
correlated to the endothelial-dependent vasodilatation. 
Furthermore, intravenous infusion of L-arginine normalised 
not just the L-arginine/ADMA ratio but also normalised the 
endothelial function [14]. 
  Perticone and colleagues studied serum ADMA levels 
and endothelial function in people with essential hyperten-
sion [55]. People with hypertension had impaired brachial 
artery FMD and increased ADMA levels. These measures 
were inversely correlated with ADMA levels independently 
accounting for 34% of the interindividual variability in peak 
flow-mediated dilatation. Infusion of L-arginine improved 
the endothelial function. 
  In a case control study, Melikian and colleagues studied 
endothelial function as measured by brachial artery FMD, 
together with plasma ADMA levels, and ciruculating mea-
sures of inflammation and oxidative stress. Black African 
people were noted to have higher ADMA levels and impai-
red endothelial function compared to the white Europeans. 
No difference in C-reactive protein levels was noted between 
the two groups. In a stepwise multiple regression model, 
ADMA was the only independent determinant of flow-
mediated dilatation (p=0.02) [56].  
  In the young Finns study involving 2096 white adults, of 
age 24-39 years, plasma ADMA levels and brachial artery 
FMD was measured along with other conventional cardio-
vascular risk factors. There was an inverse correlation bet-
ween ADMA and FMD. This inverse association between 
ADMA and FMD remained significant in a multivariate 
regression model adjusted for age, sex, conventional cardio-
vascular risk factors, estimated glomerular filtration rate and 
baseline brachial artery diameter [57]. 
  In a cross-sectional study of 121 non-diabetic people 
with proteinuria, ADMA levels correlated with the protei-
nuria as well as with the presence of secondary amyloidosis. 
Furthermore, ADMA was an independent predictor of FMD 
[58]. In a study in 24 people with Type 2 diabetes, intensive 
treatment of diabetes was shown to be associated with 
reduced serum ADMA levels and this inversely correlated to 
improved endothelial function [59]. 
  ADMA has been found to modulate coronary endothelial 
function [60] and promotes coronary spasm in small studies 
[61]. However, in a randomized, double-blind trial in 289 
patients with coronary artery disease, ADMA, L-arginine 
and coronary endothelial function as assessed by the coro-
nary artery response to local acetylcholine infusion were 
measured [62]. No correlation between coronary endothelial 
function and ADMA levels was found. In another study, 
coronary endothelial dysfunction was shown to be indepen-
dently associated with erectile dysfunction and plasma 
ADMA concentration in men with early coronary athero-
sclerosis [63]. 
  Endothelial function has been implicated as the 
underlying pathophysiological phenomenon responsible for 
slow coronary flow (SCF). Serum ADMA and L-arginine 
levels were measured in 31 people with SCF and compared 
with age-matched healthy people. People with SCF had 
significantly higher levels of ADMA and a higher L-
arginine/ADMA ratio compared to healthy people. ADMA 
levels and the L-arginine/ADMA ratio were significantly 
correlated to mean thrombolysis in myocardial infarction 
(TIMI) flow levels. On multivariate regression analysis, 
plasma ADMA levels were found to be independently 
predictive of SCF [64]. 
ADMA and Carotid Intima-Media Thickness (CIMT) 
  Increased carotid intima-media thickness (CIMT) has 
been shown to be a surrogate marker for predicting cardio-
vascular risk. In a study by Miyazaki and colleagues, step-
wise regression analysis showed plasma ADMA levels to be 
significantly correlated to CIMT [15]. In an epidemiological 
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along with CIMT. On multiple stepwise regression analysis, 
CIMT was significantly correlated with ADMA levels [65] 
and they subsequently showed that the progression of CIMT, 
over a 6 year period, was related to serum ADMA levels 
[66]. In the PREVENCION study of 922 adult patients, 
ADMA significantly predicted CIMT even after adjustment 
for cardiovascular risk factors, C-reactive protein, and renal 
function, but did not predict carotid-femoral pulse wave 
velocity, blood pressure, or hemodynamic abnormalities 
[67]. Kocak and colleagues found higher levels of ADMA in 
people without known atherosclerotic disease who were on 
peritoneal dialysis and a significant positive association 
between the ADMA levels and CIMT in these individuals 
[68].  
ADMA and Cardiovascular Disease: Clinical Studies 
  A number of studies have shown a relationship between 
raised ADMA concentrations and cardiovascular disease. 
Raised plasma ADMA concentrations have been reported in 
people with coronary artery disease (CAD) [23], peripheral 
arterial disease [69, 70], chronic heart failure [71], pulmo-
nary hypertension [72], preeclampsia [73], stroke [74], and 
hypertrophic cardiomyopathy [75]. 
  In a nested case-control study, 88 men with incident 
coronary events (fatal
 and nonfatal myocardial infarction and 
sudden cardiac death)
 and 254 age-matched controls
 from the 
population-based Monitoring of Trends and Determinants
 in 
Cardiovascular Disease/Kooperative Gesundheitsforschung 
in
  der Region Augsburg study were followed-up for a 
median of 6.2 years [76]. In this study, increased plasma 
ADMA levels were found to predict risk for coronary arterial 
events in non-smokers, but not in smokers. The authors 
speculated that this difference could be because of an 
alteration of the ADMA metabolism by a component of 
tobacco smoke [76]. 
  In a prospective trial of 225 patients undergoing haemo-
dialysis, age and ADMA levels were the strongest predictors 
of cardiovascular events and mortality after a median follow- 
up of 33 months [77]. The Coronary Artery Risk Determi-
nation investigating the Influence of ADMA Concentration 
(CARDIAC) study included 800 people with and without 
established coronary artery disease (CAD). The plasma 
ADMA concentration was 20% higher in the presence of 
established CAD (stable angina or MI) and the ADMA 
levels increased with increasing number of cardiovascular 
risk factors. The risk of CAD increased by more than two-
fold for every 1 mol/l increase in plasma ADMA [78]. In a 
prospective, nested, case-control study of middle-aged men 
from Finland, Valkonen and colleagues reported a 3.9 fold 
increased risk of acute coronary events in subjects with 
highest quartile of ADMA compared to other quartiles [23]. 
  Lu and colleagues followed-up 153 people with stable 
angina undergoing percutaneous coronary intervention for a 
duration of 16 months during which time major cardio-
vascular events occurred in 51 patients. An increased risk of 
cardiovascular events was noted with increasing levels of 
ADMA which was independent of any confounding factors 
in a multi-factorial Cox regression analysis [22]. 
  In the Ludwigshafen Risk and Cardiovascular
  Health 
(LURIC) study, 2543 people with angiographically docu-
mented CAD and 695 with no CAD were followed-up for 
5.5 years [24]. Increased all-cause mortality and death due to 
cardiovascular causes were noted in the second, third and 
fourth quarters of ADMA when compared to the lowest 
quarter (hazard ratio of 1.09, 1.40 and 2.04 respectively). 
However, the predictive value of ADMA was not statis-
tically significant in the subgroup of patients without angio-
graphically proven CAD [24].  
  In the AtheroGene study, baseline serum concentrations 
of ADMA were studied in 1874 consecutive patients with 
CAD who were then followed-up for 2.6±1.2 years. The 
primary end-point was death from cardiovascular causes or 
non-fatal myocardial infarction. The median ADMA levels 
in patients who subsequently experienced the primary end-
point was significantly higher than in patients who did not 
reach the primary end-point. The hazard ratio for the primary 
end-point was 2.48 times higher in patients whose ADMA 
was above the highest tertile compared to those in who 
ADMA was below the lowest tertile [79]. 
  In a prospective study Krempl and colleagues studied 
ADMA at baseline and 6 weeks post-PCI in patients with 
CAD (stable angina and unstable angina) compared with 
healthy individuals. They reported higher ADMA levels in 
patients with CAD compared to healthy controls. Patients 
with unstable angina had significantly higher ADMA levels 
compared to people with stable angina. Patients with 
unstable angina whose ADMA levels decreased at 6 weeks 
were found to have less frequent recurrence of cardiovas-
cular events compared to patients whose ADMA levels 
remained high post-PCI [80]. 
  Baseline ADMA levels were measured in 880 healthy 
women who were followed-up for 24 years in the Population 
Study of Women in Gothenburg [81]. The authors reported 
that a 0.15 μmol/l increase in baseline ADMA levels was 
associated with an approximately 30% increase in incident 
cardiovascular risk and 30% increase in fatal cardiovascular 
disease after adjustment for conventional cardiovascular risk 
factors, creatinine clearance and homocysteine. Plasma 
ADMA levels 0.71  μmol/l enhanced risk assessment for 
cardiovascular disease in women beyond that predicted by 
the SCORE and Framingham criteria [81]. 
  High ADMA levels have been reported to predict death 1 
year after an acute myocardial infarction. Using Cox 
multivariate analysis, ADMA above the highest tertile was a 
predictor for increased mortality (hazard ratio 4.83), when 
compared to levels in the lowest third of ADMA, even after 
adjusting for potential confounders such as acute therapy, 
biological, and clinical factors [82]. In patients with acute 
coronary syndrome, elevated baseline levels of ADMA have 
been shown to be a strong and independent predictor of 
cardiovascular outcomes, including fatal and non-fatal 
myocardial infarction, stroke and all-cause mortality [83]. 
  In a case-control study, 32 patients who had received a 
cardiac transplant underwent intravascular ultrasound of the 
coronary arteries at one month and one year following the 
cardiac transplant. Plasma ADMA levels were also mea-
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than the median and vascular remodeling were major 
outcome measures. Plasma ADMA levels were associated 
with subsequent development of intimal hyperplasia with a 
risk ratio of 2.72. ADMA levels did not correlate with 
negative coronary remodeling. Treatment with sirolimus, as 
compared with mycophenolate mofetil was associated with 
significantly lower ADMA levels and less intimal hyper-
plasia [84].  
  In a prospective study of 496 patients with peripheral 
arterial disease, ADMA and L-arginine levels were measured 
at baseline and then after 19 months follow-up. The 
occurrence of MACE (myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft, stroke, 
carotid revascularization and death) was evaluated. MACE 
occurred in 39% patients with the highest quartile of ADMA 
compared to 26% in patients with lowest quartile of ADMA. 
There was no association between L-arginine levels and the 
occurrence of MACE [70]. 
  Post-myocardial infarction cardiogenic shock is asso-
ciated with increased mortality. Nicholls and colleagues 
studied ADMA levels in patients with myocardial infarction 
who were in cardiogenic shock. ADMA levels were not only 
significantly higher in patients with cardiogenic shock but 
people with higher levels of ADMA were more likely to die 
during the 30 days follow-up compared to those who had 
low levels of ADMA. ADMA remained the only indepen-
dent predictor of mortality on multiple logistic regression 
analysis [85]. 
  In a prospective observational study, ADMA levels were 
investigated as a marker for adverse events in people 
undergoing non-cardiac surgery. Patients were followed for 
30 days after surgery for a predefined composite end point 
(death, myocardial infarction/acute coronary syndrome, 
acute heart failure, severe arrhythmia, embolism, or throm-
bosis). This study reported that elevated plasma ADMA 
concentrations were independently associated with a higher 
risk of adverse events in the per-operative and post-operative 
periods [86]. 
  Type 2 diabetes is a strong risk factor for increased 
cardiovascular mortality. In a prospective study of 125 
people with Type 2 diabetes, ADMA, L-arginine and C-
reactive protein (CRP) levels were measured. Occurrence of 
a cardiovascular event (myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass grafting, 
stroke or all-cause mortality) was defined as a composite 
end-point. ADMA and CRP levels in the highest tertile were 
associated with significantly increased hazard ratios for 
incident cardiovascular events of 2.37 and 3.63 respectively 
[87]. 
MODULATION OF ADMA LEVELS BY PHARMA-
COTHERAPY 
Statin Therapy 
  Statins are among the most effective medications for 
reducing cardiovascular risk. Evidence suggests that the 
beneficial effects of statins may not just be limited to 
reducing serum LDL-cholesterol but might also be mediated 
partly by LDL-independent pleiotropic mechanisms such as 
improvement of endothelial function by increasing the 
bioavailability of NO. Some studies have shown that high 
LDL-cholesterol levels were associated with increased 
ADMA levels [14, 88].  
  Further studies have been carried out to assess the effect 
of statin therapy on ADMA levels. In the majority of the 
studies, no impact on the ADMA levels was observed with 
statin therapy [89-92]. However rosuvastatin appeared to 
reduce ADMA levels in one study [93]. 
  Nevertheless, ADMA may have an important role in 
modulating the therapeutic response to statin therapy, in 
improving endothelium-mediated vasodilatation. The mecha-
nism of this effect of statins has been shown experimentally 
to be via up-regulation of NOS gene expression [94]. In a 
recent study, simvastatin did not enhance endothelial 
function in people with elevated ADMA levels whereas it 
did so in those with low ADMA levels. This suggests that 
although NO synthase may be upregulated by simvastatin in 
people with high ADMA levels, this may be ineffective in 
terms of enzyme activity in the presence of high levels of an 
enzyme inhibitor like ADMA. A combination of simvastatin 
and oral L-arginine improved endothelial function in people 
with high ADMA, whereas it did not change the endothelial 
response to simvastatin in patients with low ADMA [95]. As 
NO-mediated effects may play a major role in the therapeutic 
effects of statins, ADMA concentration might then be an 
important factor that influences the pleiotropic effects of 
simvastatin. 
Renin-Angiotensin System Blockers and ADMA Levels 
  Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin 2 receptor blockers (ARBs) improve endothelial 
function and NO availability in conditions like CAD, 
hypertension and diabetes [96-98]. A number of studies have 
shown ACE inhibitors and ARBs to reduce ADMA levels in 
people with hypertension, diabetes mellitus and cardiac 
syndrome X [99-102]. 
  The results of a study in eNOS knockout mice suggests 
that ADMA may also exert NO-independent effects via up-
regulation of ACE and augmentation of oxidative stress 
through angiotensin-1-dependent pathways [103]. A recent 
study on spontaneously hypertensive rats suggested that 
reduction in ADMA levels might be involved in the cardio-
protective effect of losartan [104]. 
Blood Glucose Lowering Medications and ADMA Levels 
  Type 2 diabetes has been associated with increased 
ADMA levels and cardiovascular risk [87]. ADMA and NO 
have been found to be significant determinants of insulin 
insensitivity [105], a common feature of type 2 diabetes.  
  Thiazolidinediones (rosiglitazone and pioglitazone) 
improve insulin sensitivity by acting via the peroxisome 
proliferator-activated receptors [106] and are used as blood 
glucose lowering agents in Type 2 diabetes. In a study by 
Wakino and colleagues, pioglitazone decreased plasma 
ADMA concentration by about 20% in both spontaneously 
hypertensive rats and in control normotensive Wistar-Kyoto 
(WKY) rats [107]. This effect was accompanied by the 
increase in renal expression of DDAH-2 but not DDAH-1 in 
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  Stuhlinger and colleagues found that rosiglitazone 
reduced ADMA by 30% in seven insulin-resistant non-dia-
betic hypertensive individuals [19]. In a more recent study in 
20 people with Type 2 diabetes, treatment with rosiglitazone 
was reported to have improved endothelial function but 
without reduction of ADMA levels [108]. 
  Metformin is a blood glucose-lowering agent commonly 
used in type 2 diabetes. In a study by Asgami and collea-
gues, people with type 2 diabetes were treated with met-
formin for 3 months. Serum ADMA levels were reduced by 
30% while no change in serum SDMA or L-arginine levels 
was noted [109]. Furthermore, treatment with metformin was 
found to reduce ADMA levels in young, non-obese, non-
hypertensive individuals with polycystic ovarian syndrome 
[110]. 
Aspirin and ADMA 
  Several studies have suggested a cardio-protective role 
for aspirin [111]. In a study in rats, low dose aspirin (30 
mg/kg) was assessed for its effect on LDL-induced endo-
thelial dysfunction. The results of this study suggested that 
aspirin at a lower dose (30 mg/kg) protects the endothelium 
against damages elicited by LDL in vivo, and that the 
protective effect of aspirin on endothelium is related to 
reduction of ADMA concentration by increasing DDAH 
activity [112]. 
  ADMA has been reported to accelerate cell senescence 
[113]. Aspirin has been reported to delay onset of replicative 
senescence. Along with the delayed onset of senescence, 
aspirin decreased reactive oxygen species and increased 
nitric oxide (NO) and cGMP levels. Furthermore, aspirin 
reduced the elaboration of ADMA and up-regulated the 
activity of DDAH [114]. 
Hormone Replacement Therapy and ADMA 
  It is well established that the risk of cardiovascular 
disease increases sharply after menopause in women. A 
number of retrospective and cross-sectional studies indicate 
that women treated with estrogen replacement therapy have 
improved vascular function and a lower incidence of CAD 
[115]. 
  The effect of subcutaneous oestradiol on ADMA levels 
was studied in 15 post-menopausal women [116]. The 
authors reported that estrogens can alter the catabolism and 
release of ADMA in vitro and reduce the circulating concen-
tration in vivo. Increased DDAH activity and the subsequent 
fall in ADMA was proposed to contribute to the positive 
effect of estrogen on NO synthesis [116]. 
  In a subsequent study on endothelial cells in culture, it 
was reported that oestradiol completely reverses the effects 
induced by oxidized LDL on the DDAH/ADMA/NO path-
way. This study showed that oestradiol reversed decreased 
NO release, increased ADMA production and reduced 
DDAH activity [117]. 
CONCLUSIONS 
  Since its first description as an inhibitor of NO synthesis 
in 1992, there has been accumulating evidence that ADMA 
plays an important role as a regulator of NO production in 
the endothelium. Experimental data from cell culture and 
animal experiments and cross-sectional studies in humans 
suggest an association between elevated ADMA concentra-
tions and cardiovascular diseases. Recently in vivo models 
have become available that support the pathophysiological 
relationship between ADMA and vascular disease, as over-
expression of DDAH (which leads to a reduction of 
circulating ADMA concentration by about 20%) lowers 
systemic vascular resistance and blood pressure in mice and 
protects from vascular damage in various disease models, 
whilst genetic or pharmacological disruption of DDAH 
(which increases plasma ADMA levels by some 20% in 
mice) causes hypertension and endothelial dysfunction. The, 
prospective clinical studies do suggest that ADMA may be a 
potential diagnostic tool for improved cardiovascular risk 
assessment, but the integration of ADMA into currently 
applied risk scores still needs to be performed and validated.  
  To date, approved pharmacological strategies for 
cardiovascular risk reduction have led to disappointing 
results. Most lipid-lowering and blood pressure-lowering 
drugs have failed to induce significant changes in ADMA 
concentration. By contrast, oral glucose-lowering medica-
tions for diabetes, oestrogens, and ACE inhibitors cause a 
modest reduction in ADMA. However, as all of these drugs 
influence cardiovascular risk by other mechanisms, it will be 
hard to determine whether the change in ADMA induced by 
these agents does affect cardiovascular disease risk. Specific 
therapeutic interventions in the DDAH/ADMA pathway are 
still lacking, and would be needed to perform the necessary 
randomized controlled trial to assess whether clinical benefit 
is to be gained by its modulation. 
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